Researchers evaluated the frequency and severity of pain and fatigue in patients with psoriatic arthritis receiving tumor necrosis factor inhibitors.
The FDA has approved Hulio® (adalimumab-fkjp; Mylan), a biosimilar to Humira® (adalimumab; AbbVie).
Researchers assessed the effect of clinical enthesitis in patients with psoriatic arthritis.
Researchers assessed risk for inflammatory arthritis in patients with newly diagnosed hidradenitis suppurativa.
Researchers evaluated the association of psoriasis and psoriatic arthritis with inflammatory bowel disease and other gastrointestinal illnesses.
Researchers assessed the effectiveness of steroid injections vs systemic treatment on dactylitis in patients with psoriatic arthritis.
AbbVie has submitted an application to the FDA for review of upadacitinib in the treatment of active psoriatic arthritis (PsA) in adults.
Researchers evaluated the use of TNFis vs methotrexate in reducing the risk for progression to psoriatic arthritis in patients with psoriasis.
Researchers evaluated the long-term safety and tolerability of ixekizumab in adults with psoriasis, psoriatic arthritis and axial spondyloarthritis.
Researchers performed a review of the efficacy and safety of disease-modifying antirheumatic drugs in psoriatic arthritis.